Teprotumumab increases tear production in patients with TED

Patients with thyroid eye disease (TED) treated with teprotumumab had significant reductions in the volume of lacrimal glands as well as increases in tear production, according to a poster presented at ASOPRS 52nd Annual Fall Scientific Symposium.

In this prospective longitudinal study, 20 patients treated with 8 infusions of teprotumumab for TED were included. Patients who were currently on any other medical therapy for TED or had received rituximab or tocilizumab in the past were excluded.

Patients had TED for a mean duration of 30 months before starting therapy.

The mean clinical activity score was 5 at baseline and 0.7 after treatment. After treatment in the study orbit, lacrimal gland volume decreased from 751 mm3 to 418 mm3. In the other orbit, mean lacrimal gland volume decreased from 576 mm3 to 417 mm3 (P < 0.05)

From baseline to after treatment, wetting in the study eye during Schirmer’s testing increased from 14.5 mm to 22 mm.

Margin-to-reflex distance, proptosis, steroid use, and duration of TED were not associated with lacrimal gland volume or tear production.

Reference
Ugradar S, et al. Change in Lacrimal Gland Volume and Tear Production Following Treatment with Teprotumumab. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium.